Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Century Therapeutics Inc (IPSC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/10/2025: IPSC (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
6 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $4.4
1 Year Target Price $4.4
| 3 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 50.94% | Avg. Invested days 20 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 06/10/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 48.14M USD | Price to earnings Ratio - | 1Y Target Price 4.4 |
Price to earnings Ratio - | 1Y Target Price 4.4 | ||
Volume (30-day avg) 6 | Beta 1.77 | 52 Weeks Range 0.34 - 3.29 | Updated Date 07/1/2025 |
52 Weeks Range 0.34 - 3.29 | Updated Date 07/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.27 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -19.1% | Operating Margin (TTM) 67.95% |
Management Effectiveness
Return on Assets (TTM) -5.59% | Return on Equity (TTM) -10.49% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -64515883 | Price to Sales(TTM) 0.42 |
Enterprise Value -64515883 | Price to Sales(TTM) 0.42 | ||
Enterprise Value to Revenue 1.96 | Enterprise Value to EBITDA 0.08 | Shares Outstanding 86158800 | Shares Floating 45128234 |
Shares Outstanding 86158800 | Shares Floating 45128234 | ||
Percent Insiders 24.75 | Percent Institutions 50.11 |
Analyst Ratings
Rating 3 | Target Price 4.4 | Buy 2 | Strong Buy 3 |
Buy 2 | Strong Buy 3 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Century Therapeutics Inc
Company Overview
History and Background
Century Therapeutics, Inc. was founded in 2018. It is a biotechnology company focused on developing allogeneic cell therapies for cancer. The company's evolution has been centered on leveraging iPSC technology to create off-the-shelf cell therapies.
Core Business Areas
- Allogeneic Cell Therapy Development: Developing off-the-shelf allogeneic cell therapies derived from induced pluripotent stem cells (iPSCs) for various cancers.
Leadership and Structure
The leadership team includes key executives with experience in biotechnology and cell therapy. The organizational structure focuses on research, development, and clinical operations.
Top Products and Market Share
Key Offerings
- CNT-403: This is Century's lead program, an iPSC-derived multi-antigen targeted NK cell therapy targeting solid tumors. It is currently in Phase 1 clinical trials. Competition includes companies developing other NK cell therapies, such as Fate Therapeutics and Nkarta.
- CNT-702: An iPSC-derived CAR-iT cell therapy targeting solid tumors. Currently in preclinical stage. Competitors include companies developing other CAR-T cell therapies, such as Bristol Myers Squibb and Gilead Sciences.
Market Dynamics
Industry Overview
The cell therapy market is rapidly growing, driven by advances in immunotherapy and gene editing. It is highly competitive and innovative.
Positioning
Century Therapeutics is positioned as an innovator in the allogeneic cell therapy space, particularly with its iPSC platform. Its competitive advantage lies in the potential for scalability and cost-effectiveness of off-the-shelf therapies.
Total Addressable Market (TAM)
The total addressable market for cell therapies is estimated to be in the tens of billions of dollars. Century Therapeutics is positioned to capture a share of this market by developing allogeneic cell therapies that can address a broad range of cancers.
Upturn SWOT Analysis
Strengths
- Proprietary iPSC platform
- Strong scientific team
- Potential for off-the-shelf cell therapies
- Focus on solid tumors
Weaknesses
- Early stage clinical development
- High cash burn
- Dependence on research and development success
- Limited commercial experience
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new cancer indications
- Advancements in gene editing technologies
- Increasing adoption of cell therapies
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Manufacturing challenges
Competitors and Market Share
Key Competitors
- CRSP
- GILD
- BMY
- FATE
Competitive Landscape
Century Therapeutics competes in the cell therapy market against both established pharmaceutical companies and other biotechnology companies. Its iPSC platform offers a potential advantage in terms of scalability and cost, but the company faces significant competition from companies with more advanced clinical programs.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by research and development progress, expansion of the pipeline, and clinical trial initiations.
Future Projections: Future growth is dependent on the successful development and commercialization of its cell therapy candidates. Analyst estimates vary based on clinical trial outcomes and market adoption.
Recent Initiatives: Recent initiatives include advancing clinical trials for lead programs and expanding the research and development pipeline.
Summary
Century Therapeutics is an early-stage biotechnology company with a promising iPSC-derived cell therapy platform targeting cancer. Its success hinges on the outcome of clinical trials and its ability to secure partnerships. The company's strong scientific team and innovative technology are counterbalanced by the risks inherent in drug development.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market share estimates are approximate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Century Therapeutics Inc
Exchange NASDAQ | Headquaters Philadelphia, PA, United States | ||
IPO Launch date 2021-06-18 | President, CEO & Director Dr. Brent Pfeiffenberger M.B.A., Pharm.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 140 | Website https://www.centurytx.com |
Full time employees 140 | Website https://www.centurytx.com | ||
Century Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed and refractory B-cell lymphoma. The company is also involved in the development of CNTY-308, a CD19-targeted CAR-iT cell therapy engineered with Allo-Evasion 5.0 demonstrating preclinical efficacy comparable to autologous CD19 CAR-T cells for the treatment of B-cell mediated autoimmune diseases and malignancies; and CNTY-341, A CD19/CD22 dual-targeted CAR-iT cell therapy engineered with Allo-Evasion 5.0 which pairs dual targeting and primary T-cell-like functionality in an allogeneic cell with the goal of providing a differentiated therapy for B cell malignancies that are in preclinical trial. In addition, it develops solid tumor CAR iT program exploiting Nectin-4 CAR and other validated targets, engineered with Allo-Evasion 5.0 and additional engineering aimed at overcoming the key barriers to success in solid tumors, as well as non-immune effector. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.